


CLAIM

1. A polymorphic form of a crystalline HCl salt of a trihydrate of Compound (1), wherein Compound (1) is represented by the following structural formula:



and wherein the polymorphic form of crystalline HCl salt of the trihydrate of Compound (1) is characterized by an X-ray powder diffraction pattern comprising peaks corresponding to 2-theta values measured in degrees of 7.1 ± 0.2 , 11.9 ± 0.2 , 19.2 ± 0.2 , and 12.4 ± 0.2 .


2. The polymorphic form of claim 1, wherein the X-ray powder diffraction pattern is further characterized by one or more peaks corresponding to 2-theta values measured in degrees of 16.4 ± 0.2 , 21.8 ± 0.2 , and 23.9 ± 0.2 .

3. The polymorphic form of claim 1 or claim 2, wherein the crystalline HCl salt of the trihydrate of Compound (1) is further characterized by a C^{13} SSNMR spectrum comprising one or more peaks selected from 20.7 ± 0.3 ppm, 27.4 ± 0.3 ppm, 104.8 ± 0.3 ppm, 142.5 ± 0.3 ppm, and 178.6 ± 0.3 ppm.

4. The polymorphic form of claim 3, wherein the C^{13} SSNMR spectrum further comprises one or more peaks corresponding to 154.3 ± 0.3 ppm, 20.3 ± 0.3 ppm, 132.3 ± 0.3 ppm, and 21.1 ± 0.3 ppm.

5. A pharmaceutical composition comprising a polymorphic form according to claim 1 and at least one pharmaceutically acceptable carrier or excipient.

6. A composition for use in inhibiting the replication of influenza viruses, reducing the amount of influenza viruses or treating influenza in a biological *in vitro* sample or in a subject, comprising an effective amount of a polymorphic form according to any one of claims 1-4.
7. Use of an effective amount of a polymorphic form according to any one of claims 1-4 in the manufacture of a medicament for inhibiting the replication of influenza viruses, reducing the amount of influenza viruses or treating influenza in a biological *in vitro* sample or in a subject wherein the medicament is to be administered to the sample or subject.
8. The use of claim 7, characterized in that one or more additional therapeutic agents are to be co-administered to the subject.
9. The use of claim 8, wherein the additional therapeutic agents include an anti-virus drug.
10. The use of claim 9, wherein the anti-virus drug is a neuraminidase inhibitor.
11. The use of claim 10, wherein the neuraminidase inhibitor is oseltamivir or zanamivir.
12. The use of claim 9, wherein the anti-virus drug is a polymerase inhibitor.
13. The use of claim 12, wherein the polymerase inhibitor is flavipiravir.
14. The use of any one of claims 7-13, wherein the influenza viruses are influenza A viruses.
15. A method of preparing a crystalline HCl salt of the trihydrate of Compound (1), wherein Compound (1) is represented by the following structural formula:



, comprising:

mixing Form A of an HCl salt of the hemihydrate of Compound (1) in a solvent comprising water and optionally one or more organic solvents, wherein the solvent has a water activity of 0.9 or greater, wherein the crystalline HCl salt of the trihydrate of Compound (1) is characterized by an X-ray powder diffraction pattern comprising peaks corresponding to 2-theta values measured in degrees of 7.1 ± 0.2 , 11.9 ± 0.2 , 19.2 ± 0.2 , and 12.4 ± 0.2 .

16. The method of claim 15, wherein the solvent comprises water and one or more organic solvents selected from acetone and isopropanol.

17. The method of claim 15 or claim 16, wherein the mixing is performed at a temperature in a range from 15 °C to 30 °C.